Neurocrine Biosciences (STU:NB3) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB3 Neurocrine Biosciences Inc STU:NB3
94 GF Score
Price €127.10
GF Value €177.48
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurocrine Biosciences  (STU:NB3) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Neurocrine Biosciences Cyclically Adjusted PB Ratio Related Terms


Neurocrine Biosciences Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Cyclically Adjusted PB Ratio Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.70 15.40 12.63 11.18 8.45

Neurocrine Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.87 9.47 9.28 8.18 10.05

STU:NB3 vs VTRS, ELAN, UTHR: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurocrine Biosciences Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Neurocrine Biosciences's Cyclically Adjusted PB Ratio falls into.


STU:NB3
94GF Score
Neurocrine Biosciences Inc STU:NB3
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Neurocrine Biosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Neurocrine Biosciences's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=31.798/333.9520*333.9520
=31.798

Current CPI (Jun. 2026) = 333.9520.

Neurocrine Biosciences Quarterly Data

Book Value per Share CPI Adj_Book
201609 3.602 241.428 4.982
201612 3.436 241.432 4.753
201703 2.640 243.801 3.616
201706 3.431 244.955 4.678
201709 3.323 246.819 4.496
201712 3.490 246.524 4.728
201803 3.297 249.554 4.412
201806 3.576 251.989 4.739
201809 4.249 252.439 5.621
201812 4.632 251.233 6.157
201903 3.993 254.202 5.246
201906 4.640 256.143 6.050
201909 5.723 256.759 7.444
201912 6.149 256.974 7.991
202003 6.877 258.115 8.898
202006 7.941 257.797 10.287
202009 7.343 260.280 9.421
202012 9.844 260.474 12.621
202103 10.855 264.877 13.686
202106 11.402 271.696 14.015
202109 12.251 274.310 14.915
202112 12.732 278.802 15.251
202203 13.092 287.504 15.207
202206 14.242 296.311 16.051
202209 16.407 296.808 18.460
202212 16.582 296.797 18.658
202303 15.902 301.836 17.594
202306 17.402 305.109 19.047
202309 19.257 307.789 20.894
202312 20.472 306.746 22.288
202403 21.962 312.332 23.482
202406 23.203 314.175 24.664
202409 24.073 315.301 25.497
202412 25.160 315.605 26.623
202503 23.711 319.799 24.760
202506 23.185 322.561 24.004
202509 25.639 324.800 26.361
202512 27.671 324.054 28.516
202603 29.397 330.213 29.730
202606 31.798 333.952 31.798

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Neurocrine Biosciences (STU:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €127.10 is trading 28.4% below its estimated GF Value™ of €177.48. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for STU:NB3:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €177.48 vs. price of €127.10 (28.4% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the STU:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for STU:NB3

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€127.10
Price
€177.48
GF Value